X-150776225-C-T
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2
The NM_031462.4(CD99L2):c.604G>A(p.Val202Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000367 in 1,209,951 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 148 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. 12/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_031462.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CD99L2 | NM_031462.4 | c.604G>A | p.Val202Ile | missense_variant | 9/11 | ENST00000370377.8 | NP_113650.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CD99L2 | ENST00000370377.8 | c.604G>A | p.Val202Ile | missense_variant | 9/11 | 1 | NM_031462.4 | ENSP00000359403.3 |
Frequencies
GnomAD3 genomes AF: 0.000410 AC: 46AN: 112264Hom.: 0 Cov.: 23 AF XY: 0.000465 AC XY: 16AN XY: 34438
GnomAD3 exomes AF: 0.000280 AC: 51AN: 182291Hom.: 0 AF XY: 0.000254 AC XY: 17AN XY: 66869
GnomAD4 exome AF: 0.000363 AC: 398AN: 1097687Hom.: 0 Cov.: 30 AF XY: 0.000364 AC XY: 132AN XY: 363079
GnomAD4 genome AF: 0.000410 AC: 46AN: 112264Hom.: 0 Cov.: 23 AF XY: 0.000465 AC XY: 16AN XY: 34438
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 25, 2024 | The c.616G>A (p.V206I) alteration is located in exon 9 (coding exon 9) of the CD99L2 gene. This alteration results from a G to A substitution at nucleotide position 616, causing the valine (V) at amino acid position 206 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
not provided Benign:1
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Mar 01, 2023 | CD99L2: BP4, BS2 - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at